BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dechant MJ, Fellenberg J, Scheuerpflug CG, Ewerbeck V, Debatin KM. Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int J Cancer. 2004;109:661-667. [PMID: 14999771 DOI: 10.1002/ijc.20008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Guan P, Zhu D, Wang P. Meloxicam Inhibits Apoptosis in Neurons by Deactivating Tumor Necrosis Factor Receptor Superfamily Member 25, Leading to the Decreased Cleavage of DNA Fragmentation Factor Subunit α in Alzheimer's Disease. Mol Neurobiol 2023;60:395-412. [PMID: 36279100 DOI: 10.1007/s12035-022-03091-z] [Reference Citation Analysis]
2 Chen Y, Gu Y, Xiong X, Zheng Y, Liu X, Wang W, Meng G. Roles of the adaptor protein tumor necrosis factor receptor type 1-associated death domain protein (TRADD) in human diseases. Biomedicine & Pharmacotherapy 2022;153:113467. [DOI: 10.1016/j.biopha.2022.113467] [Reference Citation Analysis]
3 Richter G, Lissat A, Kontny U. Regulated cell death and drug resistance in malignant bone tumors. Bone Cancer 2022. [DOI: 10.1016/b978-0-12-821666-8.00055-4] [Reference Citation Analysis]
4 Passarelli C, Selvatici R, Carrieri A, Di Raimo FR, Falzarano MS, Fortunato F, Rossi R, Straub V, Bushby K, Reza M, Zharaieva I, D'Amico A, Bertini E, Merlini L, Sabatelli P, Borgiani P, Novelli G, Messina S, Pane M, Mercuri E, Claustres M, Tuffery-Giraud S, Aartsma-Rus A, Spitali P, T'Hoen PAC, Lochmüller H, Strandberg K, Al-Khalili C, Kotelnikova E, Lebowitz M, Schwartz E, Muntoni F, Scapoli C, Ferlini A. Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy. Front Genet 2020;11:605. [PMID: 32719714 DOI: 10.3389/fgene.2020.00605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Marín-Rubio JL, Vela-Martín L, Fernández-Piqueras J, Villa-Morales M. FADD in Cancer: Mechanisms of Altered Expression and Function, and Clinical Implications. Cancers (Basel) 2019;11:E1462. [PMID: 31569512 DOI: 10.3390/cancers11101462] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
6 Xiao Y, Geng Z, Deng T, Wang D, Jiang L. Tumor Necrosis Factor Receptor Type 1-Associated Death Domain Protein Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia. Am J Med Sci 2019;357:111-5. [PMID: 30665491 DOI: 10.1016/j.amjms.2018.10.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Rathore R, McCallum JE, Varghese E, Florea AM, Büsselberg D. Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs). Apoptosis 2017;22:898-919. [PMID: 28424988 DOI: 10.1007/s10495-017-1375-1] [Cited by in Crossref: 141] [Cited by in F6Publishing: 154] [Article Influence: 28.2] [Reference Citation Analysis]
8 Kaur V, Kumar M, Kumar A, Kaur K, Dhillon VS, Kaur S. Pharmacotherapeutic potential of phytochemicals: Implications in cancer chemoprevention and future perspectives. Biomedicine & Pharmacotherapy 2018;97:564-86. [DOI: 10.1016/j.biopha.2017.10.124] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 10.0] [Reference Citation Analysis]
9 Ke B, Tian M, Li J, Liu B, He G. Targeting Programmed Cell Death Using Small-Molecule Compounds to Improve Potential Cancer Therapy: ANTICANCER COMPOUNDS TARGETING CELL DEATH. Med Res Rev 2016;36:983-1035. [DOI: 10.1002/med.21398] [Cited by in Crossref: 111] [Cited by in F6Publishing: 115] [Article Influence: 15.9] [Reference Citation Analysis]
10 Timirci-Kahraman O, Ozkan NE, Turan S, Farooqi AA, Verim L, Ozturk T, Inal-Gultekin G, Isbir T, Ozturk O, Yaylim I. Genetic variants in the tumor necrosis factor-related apoptosis-inducing ligand and death receptor genes contribute to susceptibility to bladder cancer. Genet Test Mol Biomarkers 2015;19:309-15. [PMID: 25955868 DOI: 10.1089/gtmb.2015.0050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
11 Fulda S. Targeting apoptosis for anticancer therapy. Seminars in Cancer Biology 2015;31:84-8. [DOI: 10.1016/j.semcancer.2014.05.002] [Cited by in Crossref: 122] [Cited by in F6Publishing: 133] [Article Influence: 15.3] [Reference Citation Analysis]
12 Functional networks of events that modulate phenotypic manifestation of cancer. Systems Biology of Cancer 2015. [DOI: 10.1017/cbo9780511979811.012] [Reference Citation Analysis]
13 Yu J, Zhang L. Apoptotic pathways and cancer. Systems Biology of Cancer 2015. [DOI: 10.1017/cbo9780511979811.017] [Reference Citation Analysis]
14 Fulda S. Targeting extrinsic apoptosis in cancer: Challenges and opportunities. Semin Cell Dev Biol. 2015;39:20-25. [PMID: 25617598 DOI: 10.1016/j.semcdb.2015.01.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 8.4] [Reference Citation Analysis]
15 Kontny U, Lissat A. Apoptosis and drug resistance in malignant bone tumors. Bone Cancer 2015. [DOI: 10.1016/b978-0-12-416721-6.00036-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
16 Zhang YC, Guo LQ, Chen X, Wang GN, Ni R, Wang MC, Wei FX. The role of death receptor 3 in the biological behavior of hepatocellular carcinoma cells. Mol Med Rep 2015;11:797-804. [PMID: 25370568 DOI: 10.3892/mmr.2014.2858] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
17 Lu J, Qin Q, Zhan L, Liu J, Zhu H, Zhang C, Xu L, Liu Z, Yang X, Cheng H, Sun X. Association of four polymorphisms in the death receptor 4 gene with cancer risk: an updated meta-analysis. Tumor Biol 2014;35:5149-58. [DOI: 10.1007/s13277-014-1667-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Fulda S. Tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Adv Exp Med Biol 2014;818:167-80. [PMID: 25001536 DOI: 10.1007/978-1-4471-6458-6_8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
19 Di Fiore R, Marcatti M, Drago-Ferrante R, D'Anneo A, Giuliano M, Carlisi D, De Blasio A, Querques F, Pastore L, Tesoriere G, Vento R. Mutant p53 gain of function can be at the root of dedifferentiation of human osteosarcoma MG63 cells into 3AB-OS cancer stem cells. Bone 2014;60:198-212. [PMID: 24373920 DOI: 10.1016/j.bone.2013.12.021] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
20 Taştemir-korkmaz D, Demirhan O, Kuleci S, Hastürk S. There is no Significant Association Between Death Receptor 4 (DR4) Gene Polymorphisms and Lung Cancer in Turkish Population. Pathol Oncol Res 2013;19:779-84. [DOI: 10.1007/s12253-013-9643-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
21 Fulda S. Harnessing Death Receptor Signaling for Cancer Treatment. Cell Death Signaling in Cancer Biology and Treatment 2013. [DOI: 10.1007/978-1-4614-5847-0_11] [Reference Citation Analysis]
22 Johnson DE. Defective Apoptosis Signaling in Cancer. Cell Death Signaling in Cancer Biology and Treatment 2013. [DOI: 10.1007/978-1-4614-5847-0_1] [Reference Citation Analysis]
23 Fulda S. Strategies to Overcome TRAIL Resistance in Cancer. Resistance to Targeted Anti-Cancer Therapeutics 2013. [DOI: 10.1007/978-1-4614-7654-2_8] [Reference Citation Analysis]
24 Fulda S. Targeting apoptosis signaling pathways for anticancer therapy. Front Oncol 2011;1:23. [PMID: 22655234 DOI: 10.3389/fonc.2011.00023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
25 Weckmann M, Kopp MV, Heinzmann A, Mattes J. Haplotypes covering the TNFSF10 gene are associated with bronchial asthma. Pediatr Allergy Immunol 2011;22:25-30. [PMID: 20961336 DOI: 10.1111/j.1399-3038.2010.01027.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
26 Ghali O, Chauveau C, Hardouin P, Broux O, Devedjian J. TNF-α's effects on proliferation and apoptosis in human mesenchymal stem cells depend on RUNX2 expression. J Bone Miner Res 2010;25:1616-26. [DOI: 10.1002/jbmr.52] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 3.6] [Reference Citation Analysis]
27 Olfa G, Christophe C, Philippe L, Romain S, Khaled H, Pierre H, Odile B, Jean-Christophe D. RUNX2 regulates the effects of TNFalpha on proliferation and apoptosis in SaOs-2 cells. Bone 2010;46:901-10. [PMID: 20053387 DOI: 10.1016/j.bone.2009.12.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
28 Isi H, Erdal M, Akdeniz S, Oral D, Ay O, Tekes S, Sula B, Edgunlu T, Balkan M, Budak T. The Tumor Necrosis Factor-A (TNF-A) Gene -308 G/A Polymorphism and the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail) Gene Polymorphisms in Behcet'S Disease. Biotechnology & Biotechnological Equipment 2010;24:2014-2019. [DOI: 10.2478/v10133-010-0055-x] [Reference Citation Analysis]
29 Kontny U. Apoptosis and Drug Resistance in Malignant Bone Tumors. Bone Cancer 2010. [DOI: 10.1016/b978-0-12-374895-9.00038-4] [Reference Citation Analysis]
30 Dakubo GD. Mitochondrial Control of Apoptosis and Cancer. Mitochondrial Genetics and Cancer 2010. [DOI: 10.1007/978-3-642-11416-8_3] [Reference Citation Analysis]
31 Fulda S. Apoptosis in Cancer Biology and Cancer Therapeutics. Essentials of Apoptosis 2009. [DOI: 10.1007/978-1-60327-381-7_26] [Reference Citation Analysis]
32 Fulda S. Tumor resistance to apoptosis. Int J Cancer. 2009;124:511-515. [PMID: 19003982 DOI: 10.1002/ijc.24064] [Cited by in Crossref: 390] [Cited by in F6Publishing: 410] [Article Influence: 26.0] [Reference Citation Analysis]
33 Dechant MJ, Scheuerpflug CG, Pauly E, van der Werff Ten Bosch J, Debatin KM, Fellenberg J. Screening, identification, and functional analysis of three novel missense mutations in the TRADD gene in children with ALL and ALPS. Pediatr Blood Cancer 2008;51:616-20. [PMID: 18661484 DOI: 10.1002/pbc.21672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
34 Macartney-Coxson DP, Hood KA, Shi HJ, Ward T, Wiles A, O'Connor R, Hall DA, Lea RA, Royds JA, Stubbs RS, Rooker S. Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level. BMC Cancer 2008;8:187. [PMID: 18590575 DOI: 10.1186/1471-2407-8-187] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 4.4] [Reference Citation Analysis]
35 Kuribayashi K, El-Deiry WS. Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol. 2008;615:201-221. [PMID: 18441595 DOI: 10.1007/978-1-4020-6554-5_10] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 4.3] [Reference Citation Analysis]
36 Langsenlehner T, Langsenlehner U, Renner W, Kapp KS, Krippl P, Hofmann G, Clar H, Pummer K, Mayer R. The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases. Prostate 2008;68:264-8. [DOI: 10.1002/pros.20682] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
37 Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther 2007;6:3219-28. [PMID: 18065493 DOI: 10.1158/1535-7163.MCT-07-0275] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
38 Koshkina NV, Kleinerman ES, Li G, Zhao CC, Wei Q, Sturgis EM. Exploratory Analysis of Fas Gene Polymorphisms in Pediatric Osteosarcoma Patients. Journal of Pediatric Hematology/Oncology 2007;29:815-21. [DOI: 10.1097/mph.0b013e3181581506] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
39 Drosopoulos K, Pintzas A. Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects. Expert Opin Ther Targets 2007;11:641-59. [PMID: 17465723 DOI: 10.1517/14728222.11.5.641] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
40 Borysenko CW, García-palacios V, Griswold RD, Li Y, Iyer AKV, Yaroslavskiy BB, Sharrow AC, Blair HC. Death receptor-3 mediates apoptosis in human osteoblasts under narrowly regulated conditions. J Cell Physiol 2006;209:1021-8. [DOI: 10.1002/jcp.20812] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
41 van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 2006;24:4998-5004. [PMID: 17075118 DOI: 10.1200/JCO.2006.06.8809] [Cited by in Crossref: 55] [Cited by in F6Publishing: 60] [Article Influence: 3.2] [Reference Citation Analysis]
42 Fulda S, Debatin K. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006;25:4798-811. [DOI: 10.1038/sj.onc.1209608] [Cited by in Crossref: 1537] [Cited by in F6Publishing: 1611] [Article Influence: 90.4] [Reference Citation Analysis]
43 Zhao XH, Gu SZ, Tian HG, Quan P, Pan BR. Clinical significance of expression of apoptotic signal proteins in gastric carcinoma tissue. World J Gastroenterol 2005; 11(25): 3846-3849 [PMID: 15991280 DOI: 10.3748/wjg.v11.i25.3846] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
44 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2005; 13(4): 565-566 [DOI: 10.11569/wcjd.v13.i4.565] [Reference Citation Analysis]
45 Fulda S, Debatin KM. Exploiting death receptor signaling pathways for tumor therapy. Biochim Biophys Acta 2004;1705:27-41. [PMID: 15585171 DOI: 10.1016/j.bbcan.2004.09.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 23] [Article Influence: 0.5] [Reference Citation Analysis]
46 Zhou SQ, Zhen YB, Wang SW, Zhang SH, Wang DR. Effect of heparanase antisense oligodeoxynucleotide on expressions of Fas and FasL in human gastricadenocarcinoma cell line SGC7901. Shijie Huaren Xiaohua Zazhi 2004; 12(10): 2287-2290 [DOI: 10.11569/wcjd.v12.i10.2287] [Reference Citation Analysis]